Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
New Jersey - July, 2006
28 articles
- Smith & Nephew Blames Sales Rep In Antitrust Probe
- Biomet Says DoJ Scales Down Antitrust Probe
- Shell Earmarks $500M For Possible Settlement
- Fairfax Hits Hedge Funds With $5B Suit
- Zimmer Tries To Clear Name In Price-Fixing Scandal
- Judge Tosses Patent Case Against Stryker
- St. Vincent Sells Off Hospital In $15M Deal
- Orthopedic Industry Braces For Possible Storm
- SEC Investigates Par Pharmaceutical
- N.J. High Court Mulls Vioxx Class Status; $30B At Stake
- America's Top Health Litigators: Drinker Biddle & Reath
- Par Pharmaceutical Hit With Securities Suits
- Judge OKs St. Vincent's $21.2M Hospital Sell-Off
- Bush Vetoes Stem-Cell Funding On "Moral" Grounds
- Senate Clears Stem-Cell Funding As Veto Looms
- Derivative Suit Targets Ulticom Execs
- Generic Drug Maker Gets Chapter 11 OK
- Shadow Of Veto Clouds Senate Stem-Cell Vote
- Parmalat Case Sours For Citigroup
- KPMG Sued By Former Employees Over Legal Fees
- Merck Wins New Jersey Vioxx Case
- Merck Strategy Still Murky As Jury Mulls Vioxx Claims
- Lawyer: Heart Attack Caused By Bad Health, Not Vioxx
- Copyright Suit Over Proposed WTC Architecture Settled
- Under Vioxx Fire, Merck Faces Fosamax Claims Too
- SEC Broadens Stock Options Probe
- J&J Subsidiaries Fight Back Generic Challenge
- Wachovia Forks Over $25M In Research Scandal